← 홈

다발성 골수종

44개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 44개
ADCCBiologicstaleChristopher StrousePhase 2

Sirolimus (Sirolimus)

Multiple Myeloma · FRα

#FR#ADC#Phase2#인기#항체약물접합체+3
효능 ORR 9%임상시험 81상태 DISCONTINUED
AntibodystalePfizerApproved

Elranatamab (Elranatamab)

Multiple Myeloma · FRα

#FR#Antibody#Approved#인기#항체+5
효능 ORR 61%임상시험 54상태 RECRUITING
CGTBiologicInternational Brain Research Fo…Phase 2

Quercetin (Quercetin)

Recurrent Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#CGT#Phase2#인기#세포유전치료+5
임상시험 54상태 RECRUITING
AntibodystalePfizerPhase 2

PF-06863135 (Elranatamab, Elranatamab (PF-06863135))

Multiple Myeloma · FRα

#FR#Antibody#Phase2#인기#항체+5
효능 ORR 61%임상시험 51상태 ACTIVE
ADCBiologicstalePfizerPhase 3

Iberdomide (Iberdomide)

Multiple Myeloma · FRα

#FR#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 92.9%임상시험 47상태 RECRUITING
AntibodystaleJanssenPhase 3

Talquetamab (Talquetamab)

Myeloma Multiple; Plasma Cell Leukemia · FRα

#FR#Antibody#Phase3#항체#면역항체+5
임상시험 40상태 DISCONTINUED
CGTBiologicstaleSung-Soo ParkPreclinical

IMiD treatment (IMiD treatment)

Multiple Myeloma, Relapsed; Multiple Myeloma (MM) · FRα

#FR#CGT#Preclinical#세포유전치료#CAR-T+5
효능 ORR 48.3%임상시험 39상태 RECRUITING
ADCBiologicstaleSanofiPhase 2

Belumosudil (Belumosudil)

Plasma Cell Myeloma Refractory · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 74%임상시험 38상태 RECRUITING
ADCBiologicstaleCanadian Myeloma Research GroupPhase 2

GSK2857916 with Pomalidomide and Dexamethasone (GSK2857916 with Pomalidomide and Dexamethasone)

Relapsed and/or Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 100%임상시험 7상태 RECRUITING
ADCBiologicstaleSanofiPhase 2

Pegenzileukin (Pegenzileukin)

Plasma Cell Myeloma Refractory · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 92.9%임상시험 5상태 RECRUITING
CGTBiologicstaleYake Biotechnology Ltd.Phase 1

APRIL CAR-T cells (APRIL CAR-T cells)

Multiple Myeloma in Relapse; Multiple Myeloma, Refractory · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 4상태 RECRUITING
ADCBiologicstaleSanofiPhase 2

SAR439459 (SAR439459)

Plasma Cell Myeloma Refractory · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 4상태 RECRUITING
ADCBiologicstaleMultiple Myeloma Research Conso…Phase 2

Selinexor, dexamethasone, ixazomib, pomalidomide (Selinexor, dexamethasone, ixazomib, pomalidomide)

Relapsed Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 3상태 ACTIVE
ADCBiologicstaleMultiple Myeloma Research Conso…Phase 2

Venetoclax, dexamethasone, ixazomib, pomalidomide (Venetoclax, dexamethasone, ixazomib, pomalidomide)

Relapsed Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 3상태 ACTIVE
ADCBiologicstaleGSKPhase 2

belantamab mafodotin (Blenrep, GSK2857916, Belantamab Mafodotin, Cyclophosphamide and Dexamethasone)

Relapsed/Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 3%임상시험 2상태 DISCONTINUED
ADCBiologicstaleGSKPhase 2

belantamab mafodotin (Blenrep, GSK2857916, Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide)

Relapsed Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 2상태 ACTIVE
AntibodystaleTakedaPhase 2

Mezagitamab (Mezagitamab)

Relapsed and/or Refractory Multiple Myeloma (RRMM) · FRα

#FR#Antibody#Phase2#항체#면역항체+4
효능 ORR 25%임상시험 2상태 ACTIVE
ADCBiologicstaleMultiple Myeloma Research Conso…Phase 2

Abemaciclib, dexamethasone, ixazomib, pomalidomide (Abemaciclib, dexamethasone, ixazomib, pomalidomide)

Relapsed Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 ACTIVE
CGTBiologicstaleM.D. Anderson Cancer Centervedotin (BV) and, in Hodgki…Phase 2

Allogeneic Anti-NY-ESO-1-TCR-IL-15-transduced Cord Blood-derived Natural Killer Cells (Allogeneic Anti-NY-ESO-1-TCR-IL-15-transduced Cord Blood-derived Natural Killer Cells)

Relapsed/Refractory Myeloma · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+5
임상시험 1상태 RECRUITING
CGTBiologicstaleLuminary TherapeuticsPhase 1

Autologous CAR-T cell therapy expressing the BAFF-ligand. (Autologous CAR-T cell therapy expressing the BAFF-ligand.)

Multiple Myeloma, Refractory; Multiple Myeloma in Relapse · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 1상태 RECRUITING

1 / 3 페이지

← 이전다음 →